Addinex Technologies Awarded $306K Grant by the NIH to Advance
Medication Adherence and Monitoring in Decentralized Clinical Trials
The Addinex system will allow researchers running clinical trials for the treatment of
substance use disorders and other afflictions to improve at-home dispensing and monitoring.
NEW YORK, NY, July 17, 2025 – Addinex Technologies, Inc., a healthcare technology company innovating in remote medication management, has been awarded a $306K Phase I Small Business Innovation Research (SBIR) grant by the National Institute on Drug Abuse (NIDA), an affiliate of the National Institutes of Health (NIH). This marks Addinex’s third federal grant from the U.S. Department of Health and Human Services, including its second from the NIH and a previous award from the Centers for Disease Control and Prevention (CDC).
This new project aims to enhance medication adherence and monitoring for Decentralized Clinical Trials (DCTs), particularly those focused on Substance Use Disorders (SUDs). Addinex’s patented dispensing system, already recognized by Fast Company as a “World Changing Idea”, enables secure at-home medication access, usage monitoring, patient education, and real-time data capture. The company will help overcome the logistical challenges of engaging and retaining patients who cannot attend in-person visits.
In collaboration with addiction treatment providers, pharmacists, clinical trial suppliers, and an experienced addiction researcher, Addinex will assess barriers to onboarding, adherence, and data collection. Based on this input, the company will enhance its mobile app and clinician portal to remotely register patients, set reminders and clinician/caregiver alerts, dispense medication, capture usage via video, and track real-time data. The project also includes a commercialization study to evaluate demand and scalability across the clinical research landscape.
“According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 48.7 million people, representing 17.3% of the U.S. population aged 12 and older, had a substance use disorder in 2022, up from 20.4 million in 2019,” stated Frank Buono, PhD, Research Scientist at Yale School of Medicine and a partner on the project. “Yet only 14.9% of those affected received treatment. Adherence is a persistent problem: in one published study, a third of patients with opioid use disorder missed at least 15 consecutive days of medication. Improving access and adherence is essential to addressing this crisis.”
“There is both a scientific and ethical imperative to develop effective SUD treatments,” stated Jay Schiff, Co-Founder and CEO of Addinex Technologies, Inc. “But around 70% of potential clinical trial participants live more than two hours from a study site, which hampers recruitment and retention. In addition, 23.7% of studies use unreliable paper diaries to track medication usage, side effects, and efficacy. Addinex aims to solve these deficiencies by promoting and improving DCTs in treatments for substance use and other maladies. With a projected CAGR of 9.8% through 2029, this market represents a significant opportunity to expand access and improve outcomes.
About Addinex Technologies, Inc.
Addinex Technologies has developed a patented, low-cost medication dispensing system designed to improve adherence and reduce misuse. The system controls medication access, educates patients, enables clinician oversight, and supports safe disposal. Addinex partners with leading hospitals and institutions and has received national recognition for its innovative approach to medication management. For more information, visit Addinex at www.addinextech.com.
Contact:
Jay Schiff, Co-Founder and CEO
Addinex Technologies, Inc.
(917) 628-8026
jschiff@addinextech.com
###